Head-to-head evidence
Bixalomer vs Colestilan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Phosphate binder · full Chronic Kidney Disease pipeline
Bixalomer · Kiklin
Marketed by Astellas Pharma
NCT00892749 · Phase 3 · completed
The study enrolled 248 participants but was open-label, single-arm, and had no placebo or active comparator, so it could not provide a controlled comparison. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Colestilan · Cholebine / BindRen
Developed by Mitsubishi Tanabe Pharma and partners
NCT00542815 · Phase 3 · completed
The study included 632 participants and reported an open-label, non-randomized comparison involving patients from earlier MCI-196 studies, rather than a newly randomized blinded trial. Its primary endpoint was the surrogate measure of serum phosphorus change, and although results were posted, the registry did not state whether the comparison with sevelamer was statistically significant, so the finding remains unclear.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bixalomer's landscape · Colestilan's landscape